Labcorp Holdings Inc. (NYSE:LH) Given Consensus Rating of “Moderate Buy” by Brokerages

Labcorp Holdings Inc. (NYSE:LH) has earned an average recommendation of “Moderate Buy” from the eleven analysts that are presently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $308.00.

A number of research firms have recently weighed in on LH. Evercore reissued an “outperform” rating and set a $300.00 price target on shares of Labcorp in a research report on Wednesday, April 8th. JPMorgan Chase & Co. upped their price target on shares of Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Labcorp in a research note on Friday, May 8th. Piper Sandler raised their price objective on shares of Labcorp from $270.00 to $300.00 and gave the stock a “neutral” rating in a report on Tuesday, February 24th. Finally, Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd.

Labcorp Trading Up 1.8%

NYSE:LH opened at $262.96 on Friday. The stock has a market cap of $21.56 billion, a price-to-earnings ratio of 23.29, a price-to-earnings-growth ratio of 1.81 and a beta of 0.91. Labcorp has a one year low of $241.81 and a one year high of $293.72. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.54 and a current ratio of 1.73. The business’s 50-day simple moving average is $263.33 and its 200 day simple moving average is $265.88.

Labcorp (NYSE:LH) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $4.09 by $0.16. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The firm had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.51 billion. During the same quarter last year, the firm earned $3.84 EPS. Labcorp’s quarterly revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. As a group, sell-side analysts predict that Labcorp will post 17.99 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Friday, May 29th will be issued a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Friday, May 29th. Labcorp’s payout ratio is currently 25.51%.

Insider Transactions at Labcorp

In other Labcorp news, CEO Adam H. Schechter sold 5,903 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $254.50, for a total transaction of $1,502,313.50. Following the sale, the chief executive officer owned 107,234 shares in the company, valued at $27,291,053. This represents a 5.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.84% of the stock is owned by insiders.

Institutional Investors Weigh In On Labcorp

Institutional investors and hedge funds have recently made changes to their positions in the company. JPL Wealth Management LLC acquired a new stake in shares of Labcorp during the third quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Labcorp in the 4th quarter worth about $26,000. Hilton Head Capital Partners LLC acquired a new position in shares of Labcorp in the 4th quarter valued at about $27,000. Eagle Bay Advisors LLC bought a new stake in shares of Labcorp during the 4th quarter valued at about $29,000. Finally, DV Equities LLC bought a new stake in shares of Labcorp during the 4th quarter valued at about $29,000. 95.94% of the stock is owned by institutional investors and hedge funds.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.